Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma. A SCARCE-PRODIGE 60 randomized phase II study
ANNÉE
2022
AUTEURS
Kim S, Ghiringhelli F, De La Fouchardiere C,Francois E, Smith MD, Samalin E, Lopez-Trabada Ataz D, Parzy A, Desrame J, Baba-Hamed N, Buecher B, Tougeron D, Bouché O, Chibaudel B, El Hajbi F, Garcia-Larnicol ML, Meurisse A, Vernerey D, Pernot S, Borg C
CONGRÈS/REVUE
ASCO
LIEN PUBLICATIONS ASSOCIÉES